PURPOSE: To prospectively evaluate the safety and efficacy of microwave ablation therapy of unresectable pulmonary @entity3 . MATERIALS AND METHODS: All @entity1 provided informed consent for this prospective institutional review board-approved study. Eighty @entity1 (30 @entity1 , 50 @entity1 ; mean age, 59.7 years    6.4; range, 48-68 years) underwent computed tomography-guided percutaneous microwave ablation of pulmonary metastatic lesions in 130 sessions. The @entity5 represented @entity3 from @entity14 , @entity0 , @entity157 , @entity1358 , and @entity153 ; there was no evidence of extrapulmonary metastasis for any @entity5 . Logistic regression analysis was used for evaluation of the statistical significance of factors affecting the end result of microwave ablation therapy. The Kaplan-Meier method was used for estimation of survival rates. RESULTS: Complete, successful ablation was achieved in 95 (73.1%) of 130 lesions. Successful @entity5 ablation was significantly more frequent for lesions with a maximal axial diameter of 3 cm or smaller (90 of 110) than for lesions greater than 3 cm in maximal axial diameter (five of 20) (P < .0001) and for peripheral lesions (80 [80%] of 100) than for centrally located lesions (15 [50%] of 30) (P = .002). The histopathologic type of the metastasis did not significantly correlate with the ablation result (P > .3). The 12- and 24-month survival rates were 91.3% and 75%, respectively. There was no intraprocedural death, and the overall 60-day mortality rate after ablation was 0%. Higher survival rates were observed in @entity1 with @entity5 -free states after successful ablation than in @entity1 with failed ablation (P = .001). The incidence of pneumothorax was 8.5% (11 of 130). An intercostal chest tube was applied in one (0.8%) of the 11 sessions. @entity548 developed in eight (6.2%) of 130 sessions. CONCLUSION: Microwave ablation therapy may be safely and effectively used as a therapeutic tool for treatment of pulmonary @entity3 . The efficacy of the treatment is primarily determined by preablation @entity5 size and location in relation to the hilum.

Microwave ablation therapy: clinical utility in treatment of pulmonary XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma'] @entity548 :: ('MESH:D006470', 'Disease') :: ['Pulmonary hemorrhage'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity153 :: ('MESH:D002283', 'Disease') :: ['bronchogenic carcinoma'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']
@entity3 :: (MESH:D009362,Disease) :: ['metastases']
